Morgan Stanley’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $28.8M | Buy |
5,689,612
+679,179
| +14% | +$3.44M | ﹤0.01% | 2452 |
|
|
2025
Q1 | $26.5M | Buy |
5,010,433
+2,149,906
| +75% | +$11.4M | ﹤0.01% | 2405 |
|
|
2024
Q4 | $19.3M | Buy |
2,860,527
+983,326
| +52% | +$6.65M | ﹤0.01% | 2782 |
|
|
2024
Q3 | $12.4M | Buy |
1,877,201
+108,889
| +6% | +$718K | ﹤0.01% | 3261 |
|
|
2024
Q2 | $13.3M | Sell |
1,768,312
-195,465
| -10% | -$1.47M | ﹤0.01% | 3089 |
|
|
2024
Q1 | $19.6M | Sell |
1,963,777
-3,188,021
| -62% | -$31.8M | ﹤0.01% | 2719 |
|
|
2023
Q4 | $50.8M | Buy |
5,151,798
+4,345,176
| +539% | +$42.8M | ﹤0.01% | 2433 |
|
|
2023
Q3 | $6.17M | Buy |
806,622
+416,393
| +107% | +$3.19M | ﹤0.01% | 3565 |
|
|
2023
Q2 | $2.92M | Buy |
390,229
+130,862
| +50% | +$978K | ﹤0.01% | 4174 |
|
|
2023
Q1 | $1.73M | Sell |
259,367
-73,804
| -22% | -$492K | ﹤0.01% | 4547 |
|
|
2022
Q4 | $2.57M | Buy |
333,171
+57,229
| +21% | +$441K | ﹤0.01% | 4297 |
|
|
2022
Q3 | $2.94M | Buy |
275,942
+54,238
| +24% | +$577K | ﹤0.01% | 4145 |
|
|
2022
Q2 | $1.81M | Buy |
221,704
+81,107
| +58% | +$660K | ﹤0.01% | 4615 |
|
|
2022
Q1 | $1.01M | Buy |
140,597
+25,096
| +22% | +$180K | ﹤0.01% | 4994 |
|
|
2021
Q4 | $1.98M | Buy |
115,501
+105,801
| +1,091% | +$1.81M | ﹤0.01% | 4593 |
|
|
2021
Q3 | $223K | Buy |
9,700
+8,564
| +754% | +$197K | ﹤0.01% | 5942 |
|
|
2021
Q2 | $41K | Buy |
+1,136
| New | +$41K | ﹤0.01% | 6749 |
|